System and method for synthesizing low-dimensional image data from high-dimensional image data using an object grid enhancement

Information

  • Patent Grant
  • 11455754
  • Patent Number
    11,455,754
  • Date Filed
    Wednesday, March 28, 2018
    6 years ago
  • Date Issued
    Tuesday, September 27, 2022
    2 years ago
Abstract
A method for processing breast tissue image data includes processing image data of a patient's breast tissue to generate a high-dimensional grid depicting one or more high-dimensional objects in the patient's breast tissue; determining a probability or confidence of each of the one or more high-dimensional objects depicted in the high-dimensional grid; and modifying one or more aspects of at least one of the one or more high-dimensional objects based at least in part on its respective determined probability or confidence to thereby generate a lower-dimensional format version of the one or more high-dimensional objects. The method may further include displaying the lower-dimensional format version of the one or more high-dimensional objects in a synthesized image of the patient's breast tissue.
Description
FIELD

The presently disclosed inventions relate to systems and methods for processing and displaying breast tissue images, and in particular to representing high-dimensional (e.g., 3D) structures present in breast tissue image data with a high-dimensional object grid, and then reducing the high-dimensional data to a low-dimensional (e.g., 2D) format version that can be incorporated within a synthesized image to be displayed to a medical professional.


BACKGROUND

Mammography has long been used to screen for breast cancer and other abnormalities. Traditionally, mammograms have been formed on x-ray film. More recently, flat panel digital imagers have been introduced that acquire a mammogram in digital form, and thereby facilitate analysis and storage of the acquired image data, and to also provide other benefits. Further, substantial attention and technological development have been dedicated to obtaining three-dimensional images of the breast using methods such as breast tomosynthesis. In contrast to the 2D images generated by legacy mammography systems, breast tomosynthesis systems construct a 3D image volume from a series of 2D projection images, each projection image obtained at a different angular displacement of an x-ray source relative to the image detector as the x-ray source is scanned over the detector. The constructed 3D image volume is typically presented as a plurality of slices of image data, the slices being mathematically reconstructed on planes typically parallel to the imaging detector. The reconstructed tomosynthesis slices reduce or eliminate the problems caused by tissue overlap and structure noise present in single slice, two-dimensional mammography imaging, by permitting a user (e.g., a radiologist or other medical professional) to scroll through the image slices to view only the structures in that slice.


Imaging systems such as tomosynthesis systems have recently been developed for breast cancer screening and diagnosis. In particular, Hologic, Inc. (hologic.com) has developed a fused, multimode mammography/tomosynthesis system that acquires one or both types of mammogram and tomosynthesis images, either while the breast remains immobilized or in different compressions of the breast. Other companies have introduced systems that include tomosynthesis imaging; e.g., which do not include the ability to also acquire a mammogram in the same compression.


Examples of systems and methods that leverage existing medical expertise in order to facilitate, optionally, the transition to tomosynthesis technology are described in U.S. Pat. No. 7,760,924, which is hereby incorporated by reference in its entirety. In particular, U.S. Pat. No. 7,760,924 describes a method of generating a synthesized 2D image, which may optionally be displayed along with tomosynthesis projection or reconstructed images, in order to assist in screening and diagnosis.


A 2D synthesized image is designed to provide a concise representation of the 3D reconstruction slices, including any clinically important and meaningful information, such as abnormal lesions and normal breast structures, while representing in relevant part a traditional 2D image. There are many different types of lesions and breast structures, which may be defined as different types of image objects having different characteristics. For any given image object visible in the 3D volume data, it is important to maintain and enhance the image characteristics (e.g., micro-calcifications, architectural distortions, etc.) as much as possible onto the 2D synthesized image. Further, when representing multiple identified objects on the 2D synthesized image, the synthesized image may appear crowded and visually confusing. Accordingly, there exists a need for more effectively processing, synthesizing and displaying breast image data.


SUMMARY

In one embodiment of the disclosed inventions, a method for processing breast tissue image data includes obtaining image data of a patient's breast tissue; processing the image data to generate a high-dimensional grid depicting one or more high-dimensional objects in the patient's breast tissue; determining a probability or confidence of each of the one or more high-dimensional objects depicted in the high-dimensional grid; and generating a lower-dimensional format version of the one or more high-dimensional objects for display in a synthesized image of the patient's breast tissue.


These and other aspects and embodiments of the disclosed inventions are described in more detail below, in conjunction with the accompanying figures.





BRIEF DESCRIPTION OF THE FIGURES

The drawings illustrate the design and utility of embodiments of the disclosed inventions, in which similar elements are referred to by common reference numerals. These drawings are not necessarily drawn to scale. In order to better appreciate how the above-recited and other advantages and objects are obtained, a more particular description of the embodiments will be rendered, which are illustrated in the accompanying drawings. These drawings depict only typical embodiments of the disclosed inventions and are not therefore to be considered limiting of its scope.



FIG. 1 is a block diagram illustrating the flow of data through an exemplary breast image acquisition and processing system in accordance with embodiments of the disclosed inventions;



FIG. 2 is a block diagram illustrating the flow of data through a 2D synthesizer employing a 3D object grid and various modules that reduce objects of the grid to a 2D format for display;



FIG. 3 illustrates a first synthesized image formed from the 3D object grid of FIG. 2 without manipulating overlapping objects, and a second synthesized image formed from the same 3D object grid, but with manipulation of overlapping objects;



FIG. 4A-4D illustrate exemplary techniques for combining objects onto one or more 2D synthesized images;



FIG. 5 illustrates an exemplary flow diagram depicting combining objects from a 3D object grid onto a 2D synthesized image; and



FIG. 6 illustrates an exemplary flow diagram depicting generating one or more 2D synthesized images using a 3D object grid.





DETAILED DESCRIPTION OF THE ILLUSTRATED EMBODIMENTS

All numeric values are herein assumed to be modified by the terms “about” or “approximately,” whether or not explicitly indicated, wherein the terms “about” and “approximately” generally refer to a range of numbers that one of skill in the art would consider equivalent to the recited value (i.e., having the same function or result). In some instances, the terms “about” and “approximately” may include numbers that are rounded to the nearest significant figure. The recitation of numerical ranges by endpoints includes all numbers within that range (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and 5).


As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the content clearly dictates otherwise. As used in this specification and the appended claims, the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise. In describing the depicted embodiments of the disclosed inventions illustrated in the accompanying figures, specific terminology is employed for the sake of clarity and ease of description. However, the disclosure of this patent specification is not intended to be limited to the specific terminology so selected, and it is to be understood that each specific element includes all technical equivalents that operate in a similar manner. It is to be further understood that the various elements and/or features of different illustrative embodiments may be combined with each other and/or substituted for each other wherever possible within the scope of this disclosure and the appended claims.


Various embodiments of the disclosed inventions are described hereinafter with reference to the figures. It should be noted that the figures are not drawn to scale and that elements of similar structures or functions are represented by like reference numerals throughout the figures. It should also be noted that the figures are only intended to facilitate the description of the embodiments. They are not intended as an exhaustive description of the invention or as a limitation on the scope of the disclosed inventions, which is defined only by the appended claims and their equivalents. In addition, an illustrated embodiment of the disclosed inventions needs not have all the aspects or advantages shown. For example, an aspect or an advantage described in conjunction with a particular embodiment of the disclosed inventions is not necessarily limited to that embodiment and can be practiced in any other embodiments even if not so illustrated.


For the following defined terms and abbreviations, these definitions shall be applied throughout this patent specification and the accompanying claims, unless a different definition is given in the claims or elsewhere in this specification:


An “acquired image” refers to an image generated while visualizing a patient's tissue. Acquired images can be generated by radiation from a radiation source impacting on a radiation detector disposed on opposite sides of a patient's tissue, as in a conventional mammogram.


A “reconstructed image” refers to an image generated from data derived from a plurality of acquired images. A reconstructed image simulates an acquired image not included in the plurality of acquired images.


A “synthesized image” refers to an artificial image generated from data derived from a plurality of acquired and/or reconstructed images. A synthesized image includes elements (e.g., objects and regions) from the acquired and/or reconstructed images, but does not necessarily correspond to an image that can be acquired during visualization. Synthesized images are constructed analysis tools.


An “Mp” image is a conventional mammogram or contrast enhanced mammogram, which are two-dimensional (2D) projection images of a breast, and encompasses both a digital image as acquired by a flat panel detector or another imaging device, and the image after conventional processing to prepare it for display (e.g., to a health professional), storage (e.g., in the PACS system of a hospital), and/or other use.


A “Tp” image is an image that is similarly two-dimensional (2D), but is acquired at a respective tomosynthesis angle between the breast and the origin of the imaging x-rays (typically the focal spot of an x-ray tube), and encompasses the image as acquired, as well as the image data after being processed for display, storage, and/or other use.


A “Tr” image is a type (or subset) of a reconstructed image that is reconstructed from tomosynthesis projection images Tp, for example, in the manner described in one or more of U.S. Pat. Nos. 7,577,282, 7,606,801, 7,760,924, and 8,571,289, the disclosures of which are fully incorporated by reference herein in their entirety, wherein a Tr image represents a slice of the breast as it would appear in a projection x-ray image of that slice at any desired angle, not only at an angle used for acquiring Tp or Mp images.


An “Ms” image is a type (or subset) of a synthesized image, in particular, a synthesized 2D projection image, which simulates mammography images, such as craniocaudal (CC) or mediolateral oblique (MLO) images, and is constructed using tomosynthesis projection images Tp, tomosynthesis reconstructed images Tr, or a combination thereof. Ms images may be provided for display to a health professional or for storage in the PACS system of a hospital or another institution. Examples of methods that may be used to generate Ms images are described in the above-incorporated U.S. Pat. Nos. 7,760,924 and 8,571,289.


It should be appreciated that Tp, Tr, Ms and Mp image data encompasses information, in whatever form, that is sufficient to describe the respective image for display, further processing, or storage. The respective Mp, Ms. Tp and Tr images are typically provided in digital form prior to being displayed, with each image being defined by information that identifies the properties of each pixel in a two-dimensional array of pixels. The pixel values typically relate to respective measured, estimated, or computed responses to X-rays of corresponding volumes in the breast, i.e., voxels or columns of tissue. In a preferred embodiment, the geometry of the tomosynthesis images (Tr and Tp) and mammography images (Ms and Mp) are matched to a common coordinate system, as described in U.S. Pat. No. 7,702,142. Unless otherwise specified, such coordinate system matching is assumed to be implemented with respect to the embodiments described in the ensuing detailed description of this patent specification.


The terms “generating an image” and “transmitting an image” respectively refer to generating and transmitting information that is sufficient to describe the image for display. The generated and transmitted information is typically digital information.


In order to ensure that a synthesized 2D image displayed to an end-user (e.g., an Ms image) includes the most clinically relevant information, it is necessary to detect and identify three-dimensional (3D) objects, such as malignant breast mass, tumors, etc., within the breast tissue. In accordance with the inventions disclosed and described herein, this information may be used to create a high-dimensional grid, e.g., a 3D grid, that helps create a more accurate and enhanced rendering of the most important features in the synthesized 2D image. The high-dimensional object grid may then be used to collapse the most clinically-significant information pertaining to the identified objects to a 2D format onto one or more synthesized 2D images. Various data reduction techniques may be applied to the identified 3D objects to ensure that the most clinically-significant objects are emphasized, and less significant objects are omitted and/or de-emphasized. Additionally, or alternatively, data reduction techniques are applied to ensure that significant features of a 3D object are enhanced, while less significant features of the 3D object are de-emphasized, especially when two objects are competing for display and prominence on the one or more 2D synthesized images. Thus, as disclosed and described herein, a 3D object grid is utilized, i.e., as a component of an algorithm, for reducing high-dimensional data (e.g., 3D tomosynthesis image data) to low-dimensional data (e.g. a 2D synthesized image).



FIG. 1 illustrates the flow of data in an exemplary image generation and display system 100, which incorporates each of synthesized image generation, object identification, and display technology. It should be understood that, while FIG. 1 illustrates a particular embodiment of a flow diagram with certain processes taking place in a particular serial order or in parallel, the claims and various other embodiments described herein are not limited to the performance of the image processing steps in any particular order, unless so specified.


More particularly, the image generation and display system 100 includes an image acquisition system 101 that acquires tomosynthesis image data for generating Tp images of a patient's breasts, using the respective three-dimensional and/or tomosynthesis acquisition methods of any of the currently available systems. If the acquisition system is a combined tomosynthesis/mammography system, Mp images may also be generated. Some dedicated tomosynthesis systems or combined tomosynthesis/mammography systems may be adapted to accept and store legacy mammogram images, (indicated by a dashed line and legend “Mplegacy” in FIG. 1) in a storage device 102, which is preferably a DICOM-compliant Picture Archiving and Communication System (PACS) storage device. Following acquisition, the tomosynthesis projection images Tp may also be transmitted to the storage device 102 (as shown in FIG. 1). The storage device 102 may further store a library of known 3D objects that may be used to identify significant 3D image patterns to the end-user. In other embodiments, a separate dedicated storage device (not shown) may be used to store the library of known 3D objects with which to identify 3D image patterns or objects.


The Tp images are transmitted from either the acquisition system 101, or from the storage device 102, or both, to a computer system configured as a reconstruction engine 103 that reconstructs the Tp images into reconstructed image “slices” Tr, representing breast slices of selected thickness and at selected orientations, as disclosed in the above-incorporated patents and applications.


Mode filters 107 are disposed between image acquisition and image display. The filters 107 may additionally include customized filters for each type of image (i.e., Tp, Mp, and Tr images) arranged to identify and highlight certain aspects of the respective image types. In this manner, each imaging mode can be tuned or configured in an optimal way for a specific purpose. For example, filters programmed for recognizing objects across various 2D image slices may be applied in order to detect image patterns that may belong to a particular high-dimensional object. The tuning or configuration may be automatic, based on the type of the image, or may be defined by manual input, for example through a user interface coupled to a display. In the illustrated embodiment of FIG. 1, the mode filters 107 are selected to highlight particular characteristics of the images that are best displayed in respective imaging modes, for example, geared towards identifying objects, highlighting masses or calcifications, identifying certain image patterns that may be constructed into a 3D object, or for creating 2D synthesized images (described below). Although FIG. 1 illustrates only one mode filter 107, it should be appreciated that any number of mode filters may be utilized in order to identify structures of interest in the breast tissue.


The imaging and display system 100 further includes a 2D image synthesizer 104 that operates substantially in parallel with the reconstruction engine 103 for generating 2D synthesized images using a combination of one or more Tp, Mp, and/or Tr images. The 2D image synthesizer 104 consumes a set of input images (e.g., Mp, Tr and/or Tp images), determines a set of most relevant features from each of the input images, and outputs one or more synthesized 2D images. The synthesized 2D image represents a consolidated synthesized image that condenses significant portions of various slices onto one image. This provides an end-user (e.g., medical personnel, radiologist, etc.) with the most clinically-relevant image data in an efficient manner, and reduces time spent on other images that may not have significant data.


One type of relevant image data to highlight in the synthesized 2D images would be relevant objects found across one or more Mp, Tr and/or Tp images. Rather than simply assessing image patterns of interest in each of the 2D image slices, it may be helpful to determine whether any of the 2D image patterns of interest belong to a larger high-dimensional structure, and if so, to combine the identified 2D image patterns into a higher-dimensional structure. This approach has several advantages, but in particular, by identifying high-dimensional structures across various slices/depths of the breast tissue, the end-user may be better informed as to the presence of a potentially significant structure that may not be easily visible in various 2D slices of the breast.


Further, instead of identifying similar image patterns in two 2D slices (that are perhaps adjacent to each other), and determining whether or not to highlight image data from one or both of the 2D slices, identifying both image patterns as belonging to the same high-dimensional structure may allow the system to make a more accurate assessment pertaining to the nature of the structure, and consequently provide significantly more valuable information to the end-user. Also, by identifying the high-dimensional structure, the structure can be more accurately depicted on the synthesized 2D image. Yet another advantage of identifying high-dimensional structures within the various captured 2D slices of the breast tissue relates to identifying a possible size/scope of the identified higher-dimensional structure. For example, once a structure has been identified, previously unremarkable image patterns that are somewhat proximate to the high-dimensional structure may now be identified as belonging to the same structure. This may provide the end-user with an indication that the high-dimensional structure is increasing in size/scope.


To this end, the 2D image synthesizer 104 generates high-dimensional object grids 120 (e.g., 3D object grids) comprising one or more high-dimensional structures (e.g., 3D objects) present in the patient's breast tissue. Several techniques may be used to construct 3D object grids 120 that identify various objects in the breast tissue. It should be appreciated that this disclosure is not limited to 3D objects and/or structures, and may refer to even higher-dimensional structures, but for simplicity, the remaining disclosure will refer to 3D objects populated in a 3D object grid 120.


In one or more embodiments, the 3D object grid 120 is in the form of a 3D (volumetric) coordinate space representing a patient's breast mass, and identifies a location, identity, size, scope, and/or other characteristics of any objects or structures found in the breast mass. Examples of such objects or structures include calcifications, spiculated lesions, benign tumors, irregular masses, dense objects, etc.


In one or more embodiments, the end-user (e.g., a medical professional such as a radiologist) can access and interact with the 3D object grid 120. In other embodiments, the 3D object grid 120 is solely used by the system processor for constructing synthesized 2D images, and the end-user may not be aware of, or have access to, the 3D object grid 120.


In accordance with the disclosed embodiments, the 2D image synthesizer 104 also includes a data reduction module 122 configured to reduce the high-dimensional data populated in the 3D object grid 120 to a lower-dimensional format suitable for representation in a 2D synthesized image. The data reduction module 122 evaluates the various objects of the 3D object grid 120, and determines what objects (or what portions of objects) should be enhanced or emphasized in a final 2D synthesized image to be displayed to the end-user. For example, a clinically significant object and a routine background breast tissue object may have regions of overlap, in which case the data reduction module 122 is preferably configured to de-emphasize portions of the background breast tissue in order to highlight the clinically significant object. Further details on various data reduction techniques that may be employed by the data reduction module 122 are described below.


The synthesized 2D images may be viewed at a display system 105. The reconstruction engine 103 and 2D image synthesizer 104 are preferably connected to a display system 105 via a fast transmission link. The display system 105 may be part of a standard acquisition workstation (e.g., of acquisition system 101), or of a standard (multi-display) review station (not shown) that is physically remote from the acquisition system 101. In some embodiments, a display connected via a communication network may be used, for example, a display of a personal computer or of a so-called tablet, smart phone or other hand-held device. In any event, the display 105 of the system is preferably able to display respective Ms, Mp, Tr, and/or Tp images concurrently, e.g., in separate side-by-side monitors of a review workstation, although the invention may still be implemented with a single display monitor, by toggling between images.


Thus, the imaging and display system 100, which is described as for purposes of illustration and not limitation, is capable of receiving and selectively displaying tomosynthesis projection images Tp, tomosynthesis reconstruction images Tr, synthesized mammogram images Ms, and/or mammogram (including contrast mammogram) images Mp, or any one or sub combination of these image types. The system 100 employs software to convert (i.e., reconstruct) tomosynthesis images Tp into images Tr, software for synthesizing mammogram images Ms, software for decomposing 3D objects, software for creating feature maps and object maps. An object of interest or feature in a source image may be considered a ‘most relevant’ feature for inclusion in a 2D synthesized image based upon the application of the object maps along with one or more algorithms and/or heuristics, wherein the algorithms assign numerical values, weights or thresholds, to pixels or regions of the respective source images based upon identified/detected objects and features of interest within the respective region or between features. The objects and features of interest may include, for example, spiculated lesions, calcifications, and the like.



FIG. 2 illustrates the 2D image synthesizer 104 in further detail. As discussed above, various image slices 218 of a tomosynthesis data set (or “stack”) 202 (e.g., filtered and/or unfiltered Mp, Tr and/or Tp images of a patient's breast tissue) are input into the 2D image synthesizer 104, and then processed to determine portions of the images to highlight in a synthesized 2D image that will be displayed on the display 105. The image slices 218 may be consecutively-captured cross-sections of a patient's breast tissue. Or, the image slices 218 may be cross-sectional images of the patient's breast tissue captured at known intervals. The tomosynthesis image stack 202 comprising the image slices 218 may be forwarded to the 2D image synthesizer 104, which evaluates each of the source images in order to (1) identify various types of objects (Tr) for possible inclusion in one or more 2D synthesized images, and/or (2) identify respective pixel regions in the images that contain the identified objects.


As shown in the illustrated embodiment, the tomosynthesis stack 202 comprises a plurality of images 218 taken at various depths/cross-sections of the patient's breast tissue. Some of the images 218 in the tomosynthesis stack 202 comprise 2D image patterns. Thus, the tomosynthesis stack 202 comprises a large number of input images containing various image patterns within the images of the stack.


For example, while the tomosynthesis stack 202 may comprise one hundred images 218 captured at various depths/cross sections of the patient's breast tissue, only a few of the images 218 may include any information of significance. Also, it should be noted that the tomosynthesis stack 202 contains 2D image patterns when viewed at differing z-dimension (depth) locations of the otherwise same x, y locations in the image slices 218, but it may be difficult to determine the 3D structures based only on the various individual images, each representing a finite cross-sectional image of the breast tissue. However, the tomosynthesis stack 202 may be effectively utilized to create the 3D object grid 120. In any event, for purposes of this patent specification, it is assumed that the 3D object grid 120 is constructed by any means, including but not limited to being created from the tomosynthesis stack 202.


The 3D object grid 120 may be considered a 3D volumetric coordinate space representing a patient's breast mass. Rather than depicting 2D image patterns at various image slices, the 3D object grid 120 preferably depicts any identified 3D objects in the entire mass (or portion thereof) that represents the patient's breast tissue. The 3D object grid 120 provides fuller detail regarding various objects in the breast mass as compared to the tomosynthesis stack 202. For example, the 3D object grid 120 may use simulation techniques to infer a shape of the 3D object, even though an image slice may not have necessarily been reconstructed at every cross-sectional depth covering the respective 3D object.


The 3D object grid 120 may comprise one or more objects, as shown in the illustrated embodiment. It should be appreciated that these objects may be predefined objects that the system has been trained to identify. However, even in healthy breast tissue that does not necessarily comprise any abnormal objects or structures, the target object recognition/enhancement modules may identify a breast background object. For example, all breast linear tissue and density tissue structures can be displayed as the breast background object. In other embodiments, “healthy” objects such as spherical shapes, oval shapes, etc., may simply be identified through one or more target object recognition/enhancement modules 210. These identified 3D objects may then be displayed on the 2D synthesized image 206; of course, out of all identified 2D objects, more clinically-significant objects may be prioritized and/or enhanced when displaying the respective object on the 2D synthesized image, as will be discussed in further detail below.


In one or more embodiments, the 2D synthesizer 104 utilizes both the tomosynthesis image stack 202 along with the created 3D object grid 120 in order to merge the relevant features into one or more 2D synthesized images 206. As shown in the 2D synthesized image, the 3D objects identified in the 3D object grid 120 are collapsed into a 2D format, but provide more detail when compared to individual image slices of the tomosynthesis image stack 202. Further, although several objects, as shown in the tomosynthesis image stack 202 overlap in the z direction, identifying them as separate 3D objects allows the system to depict both objects clearly and efficiently. Simply utilizing legacy image recognizing techniques on the tomosynthesis image stack 202 may or may not necessarily provide such an accurate synthesized 2D image 206. To explain, if there is overlap in the z direction of two structures, the two structures are essentially competing with each other for display on the 2D synthesized image 206. Thus, important aspects of both structures may be compromised. Or, only one of the two structures may be highlighted at all in the 2D synthesized image 206. Or, in yet another scenario, the 2D synthesized image may depict both structures as one amorphous structure such that an important structure goes entirely undetectable for the end-user.


It will be appreciated that identifying 3D objects as separate objects with predefined types in the 3D object grid 120 allows the system to depict the structures more accurately on the 2D synthesized image 206, and allows for various objects to be depicted simultaneously, even if there is an overlap of various objects in the coordinate space. Thus, utilizing the 3D object grid 120 has many advantages for producing a more accurate and visually-effective 2D synthesized image 206.


In one or more embodiments, data from the tomosynthesis stack 202 and the 3D object grid 120 are processed by one or more modules to produce the 2D synthesized image 206. More particularly, an object combination module 210 may be configured to identify the various objects of the 3D object grid 120, and determine a most optimal method to collapse all the objects on a 2D plane/format. For example, the object combination module 210 may determine x and y coordinates for the plurality of objects and determine whether there are overlaps between multiple objects to be displayed on the 2D synthesized image 206. In some embodiments, the object combination module 210 may further be configured to determine which of the identified objects should be displayed on the 2D synthesized image 206. This may be achieved through a training (or a “learning library” type) database 216 that stores an identity of various objects and associated weights of respective objects. The training database becomes more knowledgeable with the processing of each new patent breast image data, as the system derives 3D object models and (subsequently) detection mechanisms from this database, which will grow to include various samples of the same types of objects.


After the 3D objects are detected, then the next step is to utilize this same knowledge in synthesizing the 2D image. Since there may be many different types (or categories) of 3D objects, the weighting mechanism helps to combine the objects in the synthesis/data reduction process. For example, a dense spherical object may be weighed higher than a calcification (weighed 0.95 and 0.6 respectively in the illustrated embodiment), such that the dense spherical object may be enhanced to a greater degree as compared to a calcification. If the weight of an object is close to zero, the object combination module 210 may determine that the object need not be displayed at all, in some embodiments.


In one or more embodiments, an image details synthesis module 212 may be configured to determine what 3D objects or what areas within a 3D object should be emphasized in the 2D synthesized image 206. For example, if there is an overlap between two objects, the image details synthesis module 212 may emphasize portions of both objects, and de-emphasize other portions of both objects such that both objects are clearly viewable on the 2D synthesized image. By manipulating aspects of both objects, the end-user may be able to identify both objects clearly. It should be appreciated that without this manipulation, both objects may simply be overlayed on top of each other, such that one object may simply be masked out and missed by the end-user.


For example, the 3D object grid 120 may include a calcification area and a spiculated lesion that overlap in the z direction. Without any specially designed image synthesis, a collapsed 2D format of the spiculated lesion and a collapsed 2D format of the calcification would be displayed on top of each other. Assuming the spiculated mass is larger, the spiculated mass may envelop the calcification entirely such that it is not visible to the end-user. Instead, the image details synthesis module 212 may emphasize the outline of the center portion of the spiculated mass, while deemphasizing the middle portion of the spiculated mass such that the calcification area is visible. This image manipulation allows the end-user a clearer picture of significant objects on the 2D synthesized image 206. FIG. 3, described below, illustrates this system feature in further detail.


In some embodiments, the image details synthesis module 212 may comprise several algorithms and/or heuristics that are programmed with rules to determine what parts of an object to emphasize/de-emphasize based on the object database 216. For example, each object in the database 216 may correspond to metadata that defines most prominent and least-prominent features of the respective object. This metadata may be used by the various algorithms to determine which objects and/or which parts of objects to emphasize in the 2D synthesized images 206. By way of another example, a difference in weight between two overlapping objects may be calculated in order to determine whether both objects should be displayed. If the difference in weight is smaller than a predetermined threshold value, both objects may be displayed, but the assigned weight may be used to determine which of the two objects to emphasize over the other. However, if the difference in weight is larger than the predetermined threshold value, only the object corresponding to the higher weight may be displayed at all. For example, if a dense spherical mass and calcification area are competing for display (difference of 0.35 in weight as per the illustrated embodiment) and the threshold value is set at 0.4, both objects may be displayed, but the spiculated mass (or parts of the spiculated mass) may be highlighted relative to the calcification area. However, if the spiculated mass and a benign semi-spherical mass are overlapping (difference of 0.65 in weight as per the illustrated embodiment), only the dense spherical mass may be displayed at all. Other rules may be defined to allow the system to modify the objects or portions thereof.


As noted above (and in FIG. 1), the 2D image synthesizer 104 further includes a data reduction engine 122 configured to receive the data input from the respective image details synthesis module 212 and object combination module 210, and to reduce any 3D objects identified therein into a low level 2D format that may be inserted into the 2D synthesized image 206. In particular, and as described in further detail herein, the data reduction engine 122 accurately reduces the identified high-dimensional object of the 3D object grid 120 to a 2D format based on input received from the image details synthesis module 212, the database 216 and the object combination module 210.



FIG. 3 depicts an example of how the 3D object grid may be utilized to generate the 2D synthesized images. In the illustrated embodiment, 3D object grid 304 includes at least two 3D objects: a spiculated mass 310, and a calcification area 312. When consulting a database, the object combination module may determine that both objects are important to display in the 2D synthesized image, the spiculated mass 310 being more significant than the calcification. However, since both 3D objects 310 and 312 overlap in the z direction, the images may have to be manipulated such that both objects are still optimally displayed on the 2D synthesized image. In particular, the 2D synthesized image 306 displays a synthesized image that does not use any image manipulation techniques described in this disclosure. As shown in 2D synthesized image 306, both 3D objects 310 and 312 are competing to be displayed, and neither object is displayed very clearly. More specifically, the calcification 312 is barely visible in the 2D synthesized image 306.


By contrast, referring to 2D synthesized image 308, the techniques described with respect to FIG. 2 are utilized in order to determine what parts of the respective 3D object should be emphasized and de-emphasized such that both objects are clearly discernible in the 2D synthesized image. More particularly, although spiculated mass 310 is more significant than the calcification 312, the center portion of the spiculated mass 310 is slightly de-emphasized such that the calcification area is clearly visible. Similarly, it may be determined that the linear lines radiating from the center portion should be emphasized such that the end-user understands a size or scope of the spiculated mass. In light of the modified image corresponding to the spiculated mass 310, the calcification 312 is now visible even though both objects overlap. Thus, as shown in FIG. 3, the 2D synthesized image 308 provides more details about both 3D objects 310 and 312 when compared to 2D synthesized image 306.



FIGS. 4A-4D depict exemplary embodiments of displaying various objects of the 3D object grid, while preserving clinically-significant information. In particular, the collapsing of a 3D object into the 2D synthesized image may be achieved by the respective object combination module, image synthesis module and data reduction module that work together to display as much clinically-significant information as possible.



FIG. 4A shows an example embodiment of an intra-object combination. Intra-object combination may refer to techniques used to represent a single object (that is captured on multiple Tr image slices 404) onto the 2D synthesized image. More particularly, an identified 3D object may appear in many consecutive Tr image slices as 408a, 408b and 408c. In theory these image patterns compete with each other for representation on the 2D synthesized image. Thus, an intra-object combination requires recognizing that all the images slices belong to the same 3D object, and only showing relevant information pertaining to the 3D object on the 2D synthesized image 406. Notably, as shown in FIG. 4A, the system may determine that all the image patterns 408a, 408b and 408c from the Tr stack 404 belong to the same 3D object, and may collapse them together such that they appear as one object 410 in the 2D synthesized image 406. In one or more embodiments, techniques such as averaging, MIP (maximum intensity projection), filtering, etc. may be used for intra-object combination. Intra-object combination techniques aim to preserve the structure of the 3D object without losing valuable information from any of the image slices, while minimizing competing information from multiple image slices that do not provide valuable information and/or visually confuse the end-user.



FIG. 4B illustrates an example embodiment of an object vs background combination. Object vs. background combination may be important for creating a natural-looking 2D synthesized image. The goal of this technique is to maintain useful information from objects together with meaningful background information representative of breast tissue. In the illustrated embodiment, the Tr stack 414 comprises two Tr image slices. The first image slice comprises a background image pattern 412. The second image slice comprises an object or a portion of an object 411. In collapsing information from the Tr stack 414 to the 2D synthesized image 416, some aspects of both image slices are emphasized while other aspects are de-emphasized. For example, in 2D synthesized image 416, the object 411 is preserved, and the background 412 is also rendered, but the middle portion of the background 412 is de-emphasized.



FIG. 4C illustrates an example embodiment of inter-object combination without overlapping. In the illustrated embodiment, Tr stack 424 comprises two Tr image slices. One Tr image slice comprises object 422, and the other Tr image slice comprises object 421. As shown in the illustrated embodiment, these objects do not overlap in the z direction. Thus, when collapsing both objects onto the 2D synthesized image 426, both objects 421 and 422 are represented clearly at their respective x-y locations.



FIG. 4D illustrates an example embodiment of inter-object combination with overlap. This technique may be performed when two or more objects overlap to some degree. The two objects may be of the same type or of different types. In case of an overlap of objects, a hierarchical approach may be used to determine which object should be given precedence over the other. For example, if a higher weight is assigned to a first object, the first object may be emphasized in the 2D synthesized object, while the second object (or portions of the second object) may be de-emphasized. Or, if both objects are equally, or almost equally, important, both objects may be represented equally even if they are overlapping (and portions of both objects may be emphasized/de-emphasized such that both objects are clear in the synthesized 2D image).


In the illustrated embodiment, Tr image stack 434 comprises two Tr image slices. One Tr image slice comprises object 432, and the other Tr image slice comprises object 431. As shown in the illustrated embodiment, these objects overlap in the z direction. Thus, when collapsing the objects onto the 2D synthesized image 436, both objects 431 and 432 are represented, but are shown to overlap. Depending on weights assigned to both objects, one object may be highlighted while the other is de-emphasized. In the illustrated embodiment, both objects are represented somewhat equally, even though it is clear that they represent two separate objects. In other embodiments (not shown), if object 431 is assigned a higher weight/priority, object 431 may be emphasized in the foreground, while object 432 may be relegated to the background. Similarly, other combination techniques may be utilized to optimally represent clinically-significant information to the end-user.



FIG. 5 depicts an exemplary embodiment of collapsing information from a plurality of Tr images into a 2D synthesized image. In particular, a Tr image stack 504 may be used to create a 3D object grid similar to the 3D grid shown in FIG. 2. The Tr stack 504 illustrates four distinct objects including two calcification areas 510 and 512, a spiculated mass 514, and a spherical mass 516. As discussed in detail above, identifying these four objects as separate and distinct objects allows the system to accurately depict the objects as a whole on the 2D synthesized image 506. In the illustrated embodiment, the spiculated mass 514 is shown most prominently, while the calcifications and the spherical mass 516 are not as emphasized. This allows an end-user to easily identify the most clinically significant part of the 2D synthesized image without being overwhelmed with objects that are less-significant.



FIG. 6 is a flow diagram 600 provided to illustrate exemplary steps that may be performed in an image merge process carried out in accordance with one embodiment of the disclosed inventions. At step 602, an image data set is acquired. The image data set may be acquired by a tomosynthesis acquisition system, a combination tomosynthesis/mammography system, or by retrieving pre-existing image data from a storage device, whether locally or remotely located relative to an image display device. At step 604, a 3D object grid may be constructed by identifying various objects that are present in a 3D coordinate space representative of a patient's breast tissue. At step 606, the objects of the 3D object grid are recognized, and a relative weight/priority of each of the objects is determined. As discussed above, in some embodiments, all objects of the 3D object grid may be displayed, with some objects emphasized more than others. In other embodiments, only a subset of the recognized objects may be displayed at all, while less-significant objects are omitted.


For example, it may be determined that one object is much more clinically significant as compared to another. Or, it may be determined that two overlapping objects are equally significant. In this case, algorithms aiming to visually depict both objects optimally may be utilized, rather than highlighting one object over another. At step 608, based on the relative weight/priority of the objects, the 3D objects may be reduced to a 2D format to create the 2D synthesized image. This reduction process may highlight one object over another, in some embodiments. In other embodiment, the reduction process may highlight an outline of an object while de-emphasizing an interior of the object.


In yet another embodiment, the reduction process may emphasize one or more features that are deemed to be significant, while de-emphasizing less significant aspects of the same object. For example, in the case of a spiculated lesion, it may be important to display the blood supply lines emanating from the center of the spiculated mass, but the center of the spiculated mass, even if dense may be displayed with less emphasis. Any number of such enhancement techniques may be used in the data reduction process. At step 610, the synthesized 2D image is displayed to the end-user.


Having described exemplary embodiments, it should be appreciated that the examples described above and depicted in the accompanying figures are only illustrative, and that other embodiments and examples also are encompassed within the scope of the appended claims. For example, while the flow diagrams provided in the accompanying figures are illustrative of exemplary steps; the overall image merge process may be achieved in a variety of manners using other data merge methods known in the art. The system block diagrams are similarly representative only, illustrating functional delineations that are not to be viewed as limiting requirements of the disclosed inventions. It will also be apparent to those skilled in the art that various changes and modifications may be made to the depicted and/or described embodiments (e.g., the dimensions of various parts), without departing from the scope of the disclosed inventions, which is to be defined only by the following claims and their equivalents. The specification and drawings are, accordingly, to be regarded in an illustrative rather than restrictive sense.

Claims
  • 1. A method for processing breast tissue image data, comprising: processing an image data set including a plurality of image slices comprising image data of a patient's breast tissue to identify two or more clinically significant high-dimensional breast tissue objects in the breast tissue and to determine a clinically significant object type for each of the two or more clinically significant high-dimensional breast tissue objects;generating a high-dimensional object grid depicting each of the two or more high-dimensional breast tissue objects in the patient's breast tissue found across one or more respective image slices of the image data set;determining a confidence or probability of each of the two or more high-dimensional breast tissue objects depicted in the high-dimensional object grid;generating a synthesized image comprising a lower-dimensional format version of each of the two or more high-dimensional breast tissue objects depicted in the high-dimensional object grid based at least in part upon the confidence or probability of each of the two or more high-dimensional breast tissue objects, wherein the confidence or probability is determined based at least in part on a weight assigned to each of the two or more high-dimensional breast tissue objects, and wherein the weights assigned to the two or more high-dimensional breast tissue objects is based on the respective object type,where generating the synthesized image comprises: determining whether the two or more high-dimensional breast tissue objects are likely to overlap in the displayed synthesized image; andif it is determined that the two or more high-dimensional breast tissue objects are likely to overlap in the synthesized image, modifying at least one feature of at least one of the likely overlapping high-dimensional breast tissue objects such that one or more most clinically significant features of at least one of the likely overlapping high-dimensional breast tissue objects is displayed.
  • 2. The method of claim 1, further comprising generating the image data set including the plurality of image slices that collectively depict the patient's breast tissue, wherein the high-dimensional object grid is generated based at least in part on the plurality of image slices.
  • 3. The method of claim 1, wherein generating the synthesized image comprising the lower-dimensional format version of the two or more high-dimensional breast tissue objects includes modifying one or more aspects of at least one of the two or more high-dimensional breast tissue objects based at least in part on its respective determined confidence or probability.
  • 4. The method of claim 1, wherein the lower-dimensional format version of the two or more high-dimensional breast tissue objects is based at least in part on an intra-object combination.
  • 5. The method of claim 1, wherein the lower-dimensional format version of the two or more high-dimensional breast tissue objects is based at least in part on an inter-object combination.
  • 6. The method of claim 1, wherein the lower-dimensional format version of the two or more high-dimensional breast tissue objects is based at least in part on combining a breast tissue object with a background.
  • 7. The method of claim 1, further comprising displaying the synthesized image comprising the lower-dimensional format version of the two or more high-dimensional breast tissue objects.
  • 8. The method of claim 1, wherein the high-dimensional object grid comprises two or more high-dimensional breast tissue objects that depict normal and/or abnormal breast tissue structures.
  • 9. The method of claim 8, wherein the two or more high-dimensional breast tissue objects comprise a plurality of objects that collectively represent an entire breast parenchymal tissue structure.
  • 10. The method of claim 8, wherein each of the two or more high-dimensional breast tissue objects is associated with a respective set of attributes, each attribute representing a characteristic of the breast tissue structure depicted by the respective high-dimensional breast tissue object.
  • 11. The method of claim 10, wherein the set of attributes collectively represent one or more of a location, a size, a shape, and a morphology of the respective breast tissue structure depicted by the high-dimensional breast tissue object.
  • 12. The method of claim 8, wherein the two or more high-dimensional breast tissue objects include two or more high-dimensional breast tissue objects corresponding to a first object type, and two or more high-dimensional breast tissue objects corresponding to a second object type.
  • 13. The method of claim 12, wherein the first object type corresponds to abnormal breast lesions including micro-calcifications and masses, and the second object type corresponds to normal breast structures including nipples, pectoral muscles, and breast parenchymal tissues.
  • 14. The method of claim 13, wherein a weight assigned to objects of the first object type is greater than a weight assigned to objects of the second object type.
  • 15. The method of claim 12, further comprising using a pattern recognition method for each of the first and second object types to determine whether one or both object types are present in the image data set that depicts the patient's breast tissue.
  • 16. The method of claim 15, wherein the pattern recognition method utilizes one or more machine learning algorithms.
  • 17. The method of claim 1, further comprising, if it is determined that displaying both the two or more high-dimensional breast tissue objects that are likely to overlap in the synthesized image.
  • 18. The method of claim 1, wherein modifying at least one feature of at least one of the overlapping high-dimensional breast tissue objects comprises modifying the object to emphasizing a first portion of the modified high-dimensional breast tissue object relative to a second portion of the same object.
  • 19. A method for processing breast tissue image data, comprising: processing an image data set including a plurality of image slices comprising image data of a patient's breast tissue to identify two or more clinically significant high-dimensional breast tissue objects in the breast tissue and to determine a clinically significant object type for each of the two or more clinically significant high-dimensional breast tissue objects;generating a high-dimensional object grid depicting each of the two or more high-dimensional breast tissue objects in the patient's breast tissue found across one or more respective image slices of the image data set;determining a confidence or probability of each of the two or more high-dimensional breast tissue objects depicted in the high-dimensional object grid;generating a synthesized image comprising a lower-dimensional format version of each of the two or more high-dimensional breast tissue objects depicted in the high-dimensional object grid based at least in part upon the confidence or probability of each of the two or more high-dimensional breast tissue objects, wherein the confidence or probability is determined based at least in part on a weight assigned to each of the two or more high-dimensional breast tissue objects, and wherein the weights assigned to the two or more high-dimensional breast tissue objects is based on the respective object type,where generating the synthesized image comprises: determining whether two of the two or more high-dimensional breast tissue objects are likely to overlap in the displayed synthesized image; andif it is determined that the two of the two or more high-dimensional breast tissue objects are likely to overlap in the synthesized image: determining a difference in assigned weight of each of the two of the two or more high-dimensional breast tissue objects likely to overlap, andif the determined difference is lower than a threshold value, modifying one or more aspects of at least one of two of the two or more high-dimensional breast tissue objects, anddisplaying both of the two of the two or more high-dimensional breast tissue objects likely to overlap in the synthesized image, wherein the modification pertains to emphasizing at least a portion of the high-dimensional breast tissue object assigned the higher weight relative to the high-dimensional object assigned the lower weight.
  • 20. The method of claim 19, wherein generating the synthesized image comprising the lower-dimensional format version of the respective two or more high-dimensional breast tissue objects includes modifying one or more aspects of at least one of the two or more high-dimensional breast tissue objects to thereby emphasize high-dimensional breast tissue objects corresponding to the first object type over high-dimensional breast tissue objects corresponding to the second object type.
  • 21. The method of claim 19, further comprising, if the determined difference is equal to or greater than the threshold value, displaying only one of the two of the two or more high-dimensional breast tissue objects likely to overlap in the synthesized image, the displayed object being the one assigned the higher weight.
  • 22. The method of claim 19, wherein the first portion comprises an outline portion of the modified high-dimensional breast tissue object, and the second portion comprises a middle portion of the same object.
  • 23. The method of claim 19, further comprising, if the determined difference is lower than a threshold value, modifying at least one of the two of the two or more high-dimensional breast tissue objects to emphasizing a first portion of the modified high-dimensional breast tissue object relative to a second portion of the same object.
RELATED APPLICATIONS DATA

The present application is a National Phase entry under 35 U.S.C § 371 of International Patent Application No. PCT/US2018/024912, having an international filing date of Mar. 28, 2018, which claims the benefit under 35 U.S.C. § 119 to U.S. Provisional Patent Application Ser. No. 62/479,008, filed Mar. 30, 2017, which is incorporated by reference in its entirety into the present application.

PCT Information
Filing Document Filing Date Country Kind
PCT/US2018/024912 3/28/2018 WO
Publishing Document Publishing Date Country Kind
WO2018/183549 10/4/2018 WO A
US Referenced Citations (460)
Number Name Date Kind
3502878 Stewart Mar 1970 A
3863073 Wagner Jan 1975 A
3971950 Evans et al. Jul 1976 A
4160906 Daniels Jul 1979 A
4310766 Finkenzeller et al. Jan 1982 A
4496557 Malen et al. Jan 1985 A
4559641 Caugant et al. Dec 1985 A
4706269 Reina et al. Nov 1987 A
4744099 Huettenrauch May 1988 A
4773086 Fujita Sep 1988 A
4773087 Plewes Sep 1988 A
4819258 Kleinman et al. Apr 1989 A
4821727 Levene et al. Apr 1989 A
4907156 Doi et al. Jun 1990 A
4969174 Schied Nov 1990 A
4989227 Tirelli et al. Jan 1991 A
5018176 Romeas et al. May 1991 A
RE33634 Yanaki Jul 1991 E
5029193 Saffer Jul 1991 A
5051904 Griffith Sep 1991 A
5078142 Siczek et al. Jan 1992 A
5099846 Hardy Mar 1992 A
5129911 Siczek et al. Jul 1992 A
5133020 Giger et al. Jul 1992 A
5163075 Lubinsky Nov 1992 A
5164976 Scheid et al. Nov 1992 A
5199056 Darrah Mar 1993 A
5219351 Teubner Jun 1993 A
5240011 Assa Aug 1993 A
5279309 Taylor et al. Jan 1994 A
5280427 Magnusson Jan 1994 A
5289520 Pellegrino et al. Feb 1994 A
5343390 Doi et al. Aug 1994 A
5359637 Webbe Oct 1994 A
5365562 Toker Nov 1994 A
5386447 Siczek Jan 1995 A
5415169 Siczek et al. May 1995 A
5426685 Pellegrino et al. Jun 1995 A
5452367 Bick Sep 1995 A
5491627 Zhang et al. Feb 1996 A
5499097 Ortyn et al. Mar 1996 A
5506877 Niklason et al. Apr 1996 A
5526394 Siczek Jun 1996 A
5539797 Heidsieck et al. Jul 1996 A
5553111 Moore Sep 1996 A
5592562 Rooks Jan 1997 A
5594769 Pellegrino et al. Jan 1997 A
5596200 Sharma Jan 1997 A
5598454 Franetzki Jan 1997 A
5609152 Pellegrino et al. Mar 1997 A
5627869 Andrew et al. May 1997 A
5642433 Lee et al. Jun 1997 A
5642441 Riley et al. Jun 1997 A
5647025 Frost et al. Jul 1997 A
5657362 Giger et al. Aug 1997 A
5668889 Hara Sep 1997 A
5671288 Wilhelm et al. Sep 1997 A
5712890 Spivey Jan 1998 A
5719952 Rooks Feb 1998 A
5735264 Siczek et al. Apr 1998 A
5763871 Ortyn et al. Jun 1998 A
5769086 Ritchart et al. Jun 1998 A
5773832 Sayed et al. Jun 1998 A
5803912 Siczek et al. Sep 1998 A
5818898 Tsukamoto et al. Oct 1998 A
5828722 Ploetz Oct 1998 A
5835079 Shieh Nov 1998 A
5841124 Ortyn et al. Nov 1998 A
5872828 Niklason et al. Feb 1999 A
5875258 Ortyn et al. Feb 1999 A
5878104 Ploetz Mar 1999 A
5878746 Lemelson et al. Mar 1999 A
5896437 Ploetz Apr 1999 A
5941832 Tumey Aug 1999 A
5954650 Saito Sep 1999 A
5986662 Argiro Nov 1999 A
6005907 Ploetz Dec 1999 A
6022325 Siczek et al. Feb 2000 A
6067079 Shieh May 2000 A
6075879 Roehrig et al. Jun 2000 A
6091841 Rogers Jul 2000 A
6101236 Wang et al. Aug 2000 A
6102866 Nields et al. Aug 2000 A
6137527 Abdel-Malek Oct 2000 A
6141398 He Oct 2000 A
6149301 Kautzer et al. Nov 2000 A
6175117 Komardin Jan 2001 B1
6196715 Nambu Mar 2001 B1
6215892 Douglass et al. Apr 2001 B1
6216540 Nelson Apr 2001 B1
6219059 Argiro Apr 2001 B1
6256370 Yavus Apr 2001 B1
6233473 Sheperd May 2001 B1
6243441 Zur Jun 2001 B1
6245028 Furst et al. Jun 2001 B1
6272207 Tang Aug 2001 B1
6289235 Webber et al. Sep 2001 B1
6292530 Yavus Sep 2001 B1
6293282 Lemelson Sep 2001 B1
6327336 Gingold et al. Dec 2001 B1
6327377 Rutenberg et al. Dec 2001 B1
6341156 Baetz Jan 2002 B1
6375352 Hewes Apr 2002 B1
6389104 Bani-Hashemi et al. May 2002 B1
6411836 Patel Jun 2002 B1
6415015 Nicolas Jul 2002 B2
6424332 Powell Jul 2002 B1
6442288 Haerer Aug 2002 B1
6459925 Nields et al. Oct 2002 B1
6463181 Duarte Oct 2002 B2
6468226 McIntyre, IV Oct 2002 B1
6480565 Ning Nov 2002 B1
6501819 Unger et al. Dec 2002 B2
6556655 Chichereau Apr 2003 B1
6574304 Hsieh Jun 2003 B1
6597762 Ferrant Jul 2003 B1
6611575 Alyassin et al. Aug 2003 B1
6620111 Stephens et al. Sep 2003 B2
6626849 Huitema et al. Sep 2003 B2
6633674 Barnes Oct 2003 B1
6638235 Miller et al. Oct 2003 B2
6647092 Eberhard Nov 2003 B2
6650928 Gailly Nov 2003 B1
6683934 Zhao Jan 2004 B1
6744848 Stanton Jun 2004 B2
6748044 Sabol et al. Jun 2004 B2
6751285 Eberhard Jun 2004 B2
6758824 Miller et al. Jul 2004 B1
6813334 Koppe Nov 2004 B2
6882700 Wang Apr 2005 B2
6885724 Li Apr 2005 B2
6901156 Giger et al. May 2005 B2
6912319 Barnes May 2005 B1
6940943 Claus Sep 2005 B2
6978040 Berestov Dec 2005 B2
6987331 Koeppe Jan 2006 B2
6999554 Mertelmeier Feb 2006 B2
7022075 Grunwald et al. Apr 2006 B2
7025725 Dione et al. Apr 2006 B2
7030861 Westerman Apr 2006 B1
7110490 Eberhard Sep 2006 B2
7110502 Tsuji Sep 2006 B2
7117098 Dunlay et al. Oct 2006 B1
7123684 Jing et al. Oct 2006 B2
7127091 OpDeBeek Oct 2006 B2
7142633 Eberhard Nov 2006 B2
7218766 Eberhard May 2007 B2
7245694 Jing et al. Jul 2007 B2
7289825 Fors et al. Oct 2007 B2
7298881 Giger et al. Nov 2007 B2
7315607 Ramsauer Jan 2008 B2
7319735 Defreitas et al. Jan 2008 B2
7323692 Rowlands Jan 2008 B2
7346381 Okerlund et al. Mar 2008 B2
7406150 Minyard et al. Jul 2008 B2
7430272 Jing et al. Sep 2008 B2
7443949 Defreitas et al. Oct 2008 B2
7466795 Eberhard et al. Dec 2008 B2
7577282 Gkanatsios et al. Aug 2009 B2
7606801 Faitelson et al. Oct 2009 B2
7616801 Gkanatsios et al. Nov 2009 B2
7630533 Ruth et al. Dec 2009 B2
7634050 Muller et al. Dec 2009 B2
7640051 Krishnan Dec 2009 B2
7697660 Ning Apr 2010 B2
7702142 Ren et al. Apr 2010 B2
7705830 Westerman et al. Apr 2010 B2
7760924 Ruth et al. Jul 2010 B2
7769219 Zahniser Aug 2010 B2
7787936 Kressy Aug 2010 B2
7809175 Roehrig et al. Oct 2010 B2
7828733 Zhang et al. Nov 2010 B2
7831296 DeFreitas et al. Nov 2010 B2
7869563 DeFreitas Jan 2011 B2
7974924 Holla et al. Jul 2011 B2
7991106 Ren et al. Aug 2011 B2
8044972 Hall et al. Oct 2011 B2
8051386 Rosander et al. Nov 2011 B2
8126226 Bernard et al. Feb 2012 B2
8155421 Ren et al. Apr 2012 B2
8165365 Bernard et al. Apr 2012 B2
8532745 DeFreitas et al. Sep 2013 B2
8571289 Ruth et al. Oct 2013 B2
8594274 Hoernig et al. Nov 2013 B2
8677282 Cragun et al. Mar 2014 B2
8712127 Ren et al. Apr 2014 B2
8897535 Ruth et al. Nov 2014 B2
8983156 Periaswamy et al. Mar 2015 B2
9020579 Smith Apr 2015 B2
9075903 Marshall Jul 2015 B2
9084579 Ren et al. Jul 2015 B2
9119599 Itai Sep 2015 B2
9129362 Jerebko Sep 2015 B2
9289183 Karssemeijer Mar 2016 B2
9451924 Bernard Sep 2016 B2
9456797 Ruth et al. Oct 2016 B2
9478028 Parthasarathy Oct 2016 B2
9589374 Gao Mar 2017 B1
9592019 Sugiyama Mar 2017 B2
9805507 Chen Oct 2017 B2
9808215 Ruth et al. Nov 2017 B2
9811758 Ren et al. Nov 2017 B2
9901309 DeFreitas et al. Feb 2018 B2
10008184 Kreeger et al. Jun 2018 B2
10010302 Ruth et al. Jul 2018 B2
10092358 DeFreitas Oct 2018 B2
10111631 Gkanatsios Oct 2018 B2
10242490 Karssemeijer Mar 2019 B2
10335094 DeFreitas Jul 2019 B2
10357211 Smith Jul 2019 B2
10410417 Chen et al. Sep 2019 B2
10413263 Ruth et al. Sep 2019 B2
10444960 Marshall Oct 2019 B2
10456213 DeFreitas Oct 2019 B2
10573276 Kreeger et al. Feb 2020 B2
10575807 Gkanatsios Mar 2020 B2
10595954 DeFreitas Mar 2020 B2
10624598 Chen Apr 2020 B2
10977863 Chen Apr 2021 B2
10978026 Kreeger Apr 2021 B2
20010038681 Stanton et al. Nov 2001 A1
20010038861 Hsu et al. Nov 2001 A1
20020012450 Tsuji Jan 2002 A1
20020050986 Inoue May 2002 A1
20020075997 Unger et al. Jun 2002 A1
20020113681 Byram Aug 2002 A1
20020122533 Marie et al. Sep 2002 A1
20020188466 Barrette et al. Dec 2002 A1
20020193676 Bodicker Dec 2002 A1
20030007598 Wang Jan 2003 A1
20030018272 Treado et al. Jan 2003 A1
20030026386 Tang Feb 2003 A1
20030048260 Matusis Mar 2003 A1
20030073895 Nields et al. Apr 2003 A1
20030095624 Eberhard et al. May 2003 A1
20030097055 Yanof May 2003 A1
20030128893 Castorina Jul 2003 A1
20030135115 Burdette et al. Jul 2003 A1
20030169847 Karellas Sep 2003 A1
20030194050 Eberhard Oct 2003 A1
20030194121 Eberhard et al. Oct 2003 A1
20030195433 Turovskiy Oct 2003 A1
20030210254 Doan Nov 2003 A1
20030212327 Wang Nov 2003 A1
20030215120 Uppaluri Nov 2003 A1
20040008809 Webber Jan 2004 A1
20040008900 Jabri et al. Jan 2004 A1
20040008901 Avinash Jan 2004 A1
20040036680 Davis Feb 2004 A1
20040047518 Tiana Mar 2004 A1
20040052328 Saboi Mar 2004 A1
20040064037 Smith Apr 2004 A1
20040066884 Claus Apr 2004 A1
20040066904 Eberhard et al. Apr 2004 A1
20040070582 Smith et al. Apr 2004 A1
20040077938 Mark et al. Apr 2004 A1
20040081273 Ning Apr 2004 A1
20040094167 Brady May 2004 A1
20040101095 Jing et al. May 2004 A1
20040109028 Stern et al. Jun 2004 A1
20040109529 Eberhard et al. Jun 2004 A1
20040127789 Ogawa Jul 2004 A1
20040138569 Grunwald Jul 2004 A1
20040171933 Stoller et al. Sep 2004 A1
20040171986 Tremaglio, Jr. et al. Sep 2004 A1
20040267157 Miller et al. Dec 2004 A1
20050047636 Gines et al. Mar 2005 A1
20050049521 Miller et al. Mar 2005 A1
20050063509 Defreitas et al. Mar 2005 A1
20050078797 Danielsson et al. Apr 2005 A1
20050084060 Seppi et al. Apr 2005 A1
20050089205 Kapur Apr 2005 A1
20050105679 Wu et al. May 2005 A1
20050107689 Sasano May 2005 A1
20050111718 MacMahon May 2005 A1
20050113681 DeFreitas et al. May 2005 A1
20050113715 Schwindt et al. May 2005 A1
20050124845 Thomadsen et al. Jun 2005 A1
20050135555 Claus Jun 2005 A1
20050135664 Kaufhold Jun 2005 A1
20050226375 Eberhard Oct 2005 A1
20060009693 Hanover et al. Jan 2006 A1
20060018526 Avinash Jan 2006 A1
20060025680 Jeune-Iomme Feb 2006 A1
20060030784 Miller et al. Feb 2006 A1
20060074288 Kelly et al. Apr 2006 A1
20060098855 Gkanatsios et al. May 2006 A1
20060129062 Nicoson et al. Jun 2006 A1
20060132508 Sadikali Jun 2006 A1
20060147099 Marshall et al. Jul 2006 A1
20060155209 Miller et al. Jul 2006 A1
20060197753 Hotelling Sep 2006 A1
20060210131 Wheeler, Jr. Sep 2006 A1
20060228012 Masuzawa Oct 2006 A1
20060238546 Handley Oct 2006 A1
20060257009 Wang Nov 2006 A1
20060269040 Mertelmeier Nov 2006 A1
20060291618 Eberhard et al. Dec 2006 A1
20070019846 Bullitt et al. Jan 2007 A1
20070030949 Jing et al. Feb 2007 A1
20070036265 Jing et al. Feb 2007 A1
20070046649 Reiner Mar 2007 A1
20070052700 Wheeler et al. Mar 2007 A1
20070076844 Defreitas et al. Apr 2007 A1
20070114424 Danielsson et al. May 2007 A1
20070118400 Morita et al. May 2007 A1
20070156451 Gering Jul 2007 A1
20070223651 Wagenaar et al. Sep 2007 A1
20070225600 Weibrecht et al. Sep 2007 A1
20070236490 Casteele Oct 2007 A1
20070242800 Jing et al. Oct 2007 A1
20070263765 Wu Nov 2007 A1
20070274585 Zhang et al. Nov 2007 A1
20080019581 Gkanatsios et al. Jan 2008 A1
20080043905 Hassanpourgol Feb 2008 A1
20080045833 DeFreitas et al. Feb 2008 A1
20080101537 Sendai May 2008 A1
20080114614 Mahesh et al. May 2008 A1
20080125643 Huisman May 2008 A1
20080130979 Ren Jun 2008 A1
20080139896 Baumgart Jun 2008 A1
20080152086 Hall Jun 2008 A1
20080165136 Christie et al. Jul 2008 A1
20080187095 Boone et al. Aug 2008 A1
20080198966 Hjarn Aug 2008 A1
20080221479 Ritchie Sep 2008 A1
20080229256 Shibaike Sep 2008 A1
20080240533 Piron et al. Oct 2008 A1
20080297482 Weiss Dec 2008 A1
20090003519 DeFreitas Jan 2009 A1
20090005668 West et al. Jan 2009 A1
20090010384 Jing et al. Jan 2009 A1
20090034684 Bernard Feb 2009 A1
20090037821 O'Neal et al. Feb 2009 A1
20090079705 Sizelove et al. Mar 2009 A1
20090080594 Brooks et al. Mar 2009 A1
20090080602 Brooks et al. Mar 2009 A1
20090080604 Shores et al. Mar 2009 A1
20090080752 Ruth Mar 2009 A1
20090080765 Bernard et al. Mar 2009 A1
20090087067 Khorasani Apr 2009 A1
20090123052 Ruth May 2009 A1
20090129644 Daw et al. May 2009 A1
20090135997 Defreitas et al. May 2009 A1
20090138280 Morita et al. May 2009 A1
20090143674 Nields Jun 2009 A1
20090167702 Nurmi Jul 2009 A1
20090171244 Ning Jul 2009 A1
20090238424 Arakita Sep 2009 A1
20090259958 Ban Oct 2009 A1
20090268865 Ren et al. Oct 2009 A1
20090278812 Yasutake Nov 2009 A1
20090296882 Gkanatsios et al. Dec 2009 A1
20090304147 Jing et al. Dec 2009 A1
20100034348 Yu Feb 2010 A1
20100049046 Peiffer Feb 2010 A1
20100054400 Ren et al. Mar 2010 A1
20100079405 Bernstein Apr 2010 A1
20100086188 Ruth et al. Apr 2010 A1
20100088346 Urness et al. Apr 2010 A1
20100098214 Star-Lack et al. Apr 2010 A1
20100105879 Katayose et al. Apr 2010 A1
20100121178 Krishnan May 2010 A1
20100131294 Venon May 2010 A1
20100131482 Linthicum et al. May 2010 A1
20100135558 Ruth et al. Jun 2010 A1
20100152570 Navab Jun 2010 A1
20100166267 Zhang Jul 2010 A1
20100195882 Ren et al. Aug 2010 A1
20100208037 Sendai Aug 2010 A1
20100231522 Li Sep 2010 A1
20100246909 Blum Sep 2010 A1
20100259561 Forutanpour et al. Oct 2010 A1
20100259645 Kaplan Oct 2010 A1
20100260316 Stein et al. Oct 2010 A1
20100280375 Zhang Nov 2010 A1
20100293500 Cragun Nov 2010 A1
20110018817 Kryze Jan 2011 A1
20110019891 Puong Jan 2011 A1
20110054944 Sandberg et al. Mar 2011 A1
20110069808 Defreitas et al. Mar 2011 A1
20110069906 Park Mar 2011 A1
20110087132 DeFreitas et al. Apr 2011 A1
20110105879 Masumoto May 2011 A1
20110109650 Kreeger May 2011 A1
20110110576 Kreeger May 2011 A1
20110150447 Li Jun 2011 A1
20110163939 Tam et al. Jul 2011 A1
20110178389 Kumar et al. Jul 2011 A1
20110182402 Partain Jul 2011 A1
20110234630 Batman et al. Sep 2011 A1
20110237927 Brooks et al. Sep 2011 A1
20110242092 Kashiwagi Oct 2011 A1
20110310126 Georgiev et al. Dec 2011 A1
20120014504 Jang Jan 2012 A1
20120014578 Karssemeijer Jan 2012 A1
20120069951 Toba Mar 2012 A1
20120131488 Karlsson et al. May 2012 A1
20120133600 Marshall May 2012 A1
20120133601 Marshall May 2012 A1
20120134464 Hoernig et al. May 2012 A1
20120148151 Hamada Jun 2012 A1
20120189092 Jerebko Jul 2012 A1
20120194425 Buelow Aug 2012 A1
20120238870 Smith et al. Sep 2012 A1
20120293511 Mertelmeier Nov 2012 A1
20130022165 Jang Jan 2013 A1
20130044861 Muller Feb 2013 A1
20130059758 Haick Mar 2013 A1
20130108138 Nakayama May 2013 A1
20130121569 Yadav May 2013 A1
20130121618 Yadav May 2013 A1
20130202168 Jerebko Aug 2013 A1
20130259193 Packard Oct 2013 A1
20140033126 Kreeger Jan 2014 A1
20140035811 Guehring Feb 2014 A1
20140064444 Oh Mar 2014 A1
20140073913 DeFreitas et al. Mar 2014 A1
20140219534 Wiemker et al. Aug 2014 A1
20140219548 Wels et al. Aug 2014 A1
20140327702 Kreeger et al. Nov 2014 A1
20140328517 Gluncic Nov 2014 A1
20150052471 Chen et al. Feb 2015 A1
20150061582 Smith et al. Apr 2015 A1
20150238148 Georgescu Aug 2015 A1
20150302146 Marshall Oct 2015 A1
20150309712 Marshall Oct 2015 A1
20150317538 Ren et al. Nov 2015 A1
20150331995 Zhao Nov 2015 A1
20160000399 Halmann et al. Jan 2016 A1
20160022364 DeFreitas et al. Jan 2016 A1
20160051215 Chen Feb 2016 A1
20160078645 Abdurahman et al. Mar 2016 A1
20160140749 Erhard May 2016 A1
20160228034 Gluncic Aug 2016 A1
20160235380 Smith Aug 2016 A1
20160367210 Gkanatsios Dec 2016 A1
20170071562 Suzuki Mar 2017 A1
20170262737 Rabinovich Sep 2017 A1
20180047211 Chen et al. Feb 2018 A1
20180137385 Ren May 2018 A1
20180144244 Masoud May 2018 A1
20180256118 DeFreitas Sep 2018 A1
20190015173 DeFreitas Jan 2019 A1
20190043456 Kreeger Feb 2019 A1
20190290221 Smith Sep 2019 A1
20200046303 DeFreitas Feb 2020 A1
20200093562 DeFreitas Mar 2020 A1
20200184262 Chui Jun 2020 A1
20200205928 DeFreitas Jul 2020 A1
20200253573 Gkanatsios Aug 2020 A1
20200345320 Chen Nov 2020 A1
20200390404 DeFreitas Dec 2020 A1
20210000553 St. Pierre Jan 2021 A1
20210100518 Chui Apr 2021 A1
20210100626 St. Pierre Apr 2021 A1
20210113167 Chui Apr 2021 A1
20220005277 Chen Jan 2022 A1
20220013089 Kreeger Jan 2022 A1
20220192615 Chui Jun 2022 A1
Foreign Referenced Citations (98)
Number Date Country
2014339982 May 2016 AU
1846622 Oct 2006 CN
202161328 Mar 2012 CN
102429678 May 2012 CN
107440730 Dec 2017 CN
102010009295 Aug 2011 DE
102011087127 May 2013 DE
775467 May 1997 EP
982001 Mar 2000 EP
1428473 Jun 2004 EP
2236085 Jun 2010 EP
2215600 Aug 2010 EP
2301432 Mar 2011 EP
2491863 Aug 2012 EP
1986548 Jan 2013 EP
2656789 Oct 2013 EP
2823464 Jan 2015 EP
2823765 Jan 2015 EP
3060132 Apr 2019 EP
H09-198490 Jul 1997 JP
H09-238934 Sep 1997 JP
10-33523 Feb 1998 JP
H10-33523 Feb 1998 JP
2000-200340 Jul 2000 JP
2002-282248 Oct 2002 JP
2003-189179 Jul 2003 JP
2003-199737 Jul 2003 JP
2003-531516 Oct 2003 JP
2006-519634 Aug 2006 JP
2006-312026 Nov 2006 JP
2007-130487 May 2007 JP
2007-330334 Dec 2007 JP
2007-536968 Dec 2007 JP
2008-068032 Mar 2008 JP
2009-034503 Feb 2009 JP
2009-522005 Jun 2009 JP
2009-526618 Jul 2009 JP
2009-207545 Sep 2009 JP
2010-137004 Jun 2010 JP
2011-110175 Jun 2011 JP
2012-501750 Jan 2012 JP
2012011255 Jan 2012 JP
2012-061196 Mar 2012 JP
2013-244211 Dec 2013 JP
2014-507250 Mar 2014 JP
2014-534042 Dec 2014 JP
2015-506794 Mar 2015 JP
2015-144632 Aug 2015 JP
2016-198197 Dec 2015 JP
10-2015-0010515 Jan 2015 KR
10-2017-0062839 Jun 2017 KR
9005485 May 1990 WO
9317620 Sep 1993 WO
9406352 Mar 1994 WO
199700649 Jan 1997 WO
199816903 Apr 1998 WO
0051484 Sep 2000 WO
2003020114 Mar 2003 WO
2005051197 Jun 2005 WO
2005110230 Nov 2005 WO
2005110230 Nov 2005 WO
2005112767 Dec 2005 WO
2005112767 Dec 2005 WO
2006055830 May 2006 WO
2006058160 Jun 2006 WO
2007095330 Aug 2007 WO
08014670 Feb 2008 WO
2008047270 Apr 2008 WO
2008054436 May 2008 WO
2009026587 Feb 2009 WO
2010028208 Mar 2010 WO
2010059920 May 2010 WO
2011008239 Jan 2011 WO
2011043838 Apr 2011 WO
2011065950 Jun 2011 WO
2011073864 Jun 2011 WO
2011091300 Jul 2011 WO
2012001572 Jan 2012 WO
2012068373 May 2012 WO
2012063653 May 2012 WO
2012112627 Aug 2012 WO
2012122399 Sep 2012 WO
2013001439 Jan 2013 WO
2013035026 Mar 2013 WO
2013078476 May 2013 WO
WO-2013123091 Aug 2013 WO
2014149554 Sep 2014 WO
WO2014207080 Dec 2014 WO
WO-2014207080 Dec 2014 WO
2015061582 Apr 2015 WO
2015066650 May 2015 WO
2015130916 Sep 2015 WO
2016103094 Jun 2016 WO
2016184746 Nov 2016 WO
2018183548 Oct 2018 WO
2018183550 Oct 2018 WO
WO2018183549 Oct 2018 WO
2018236565 Dec 2018 WO
Non-Patent Literature Citations (74)
Entry
M. Ertas, A. Akan, I. Yildirim, A. Dinler and M. Kamasak, “2D versus 3D total variation minimization in digital breast tomosynthesis,” 2015 IEEE International Conference on Imaging Systems and Techniques (IST), Macau, 2015, pp. 1-4, doi: 10.1109/IST.2015.7294553. (Year: 2015).
B. E. Caroline and N. Vaijayanthi, “Computer aided detection of masses in digital breast tomosynthesis: A review,” 2012 International Conference on Emerging Trends in Science, Engineering and Technology (INCOSET), Tiruchirappalli, 2012, pp. 186-191, doi: 10.1109/INCOSET.2012.6513903 (Year: 2012).
International Search Report and Written Opinion dated Jun. 8, 2018 for PCT application No. PCT/US2018/024912, applicant Hologic, Inc., 10 pages.
Non-Final Office Action for U.S. Appl. No. 16/497,767 dated Feb. 19, 2021.
U.S. Appl. No. 16/497,767, Office Action dated Jul. 16, 2021, 26 pages.
PCT International Preliminary Report on Patentability in International Application PCT/US2018/024912, dated Oct. 10, 2019, 7 pages.
“Filtered Back Projection”, (Nygren), published May 8, 2007, URL: http://web.archive.org/web/19991010131715/http://www.owlnet.rice.edu/˜elec539/Projects97/cult/node2.html, 2 pgs.
Berg, WA et al., “Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer”, JAMA 299:2151-2163, 2008.
Carton, AK, et al., “Dual-energy contrast-enhanced digital breast tomosynthesis—a feasibility study”, BR J Radiol. Apr. 2010;83 (988):344-50.
Chen, SC, et al., “Initial clinical experience with contrast-enhanced digital breast tomosynthesis”, Acad Radio. Feb. 2007 14(2):229-38.
Diekmann, F., et al., “Digital mammography using iodine-based contrast media: initial clinical experience with dynamic contrast medium enhancement”, Invest Radiol 2005; 40:397-404.
Dromain C., et al., “Contrast enhanced spectral mammography: a multi-reader study”, RSNA 2010, 96th Scientific Assembly and Scientific Meeting.
Dromain, C., et al., “Contrast-enhanced digital mammography”, Eur J Radiol. 2009; 69:34-42.
Freiherr, G., “Breast tomosynthesis trials show promise”, Diagnostic Imaging—San Francisco 2005, V27; N4:42-48.
Giger et al. “Development of a smart workstation for use in mammography”, in Proceedings of SPIE, vol. 1445 (1991), p. 101103; 4 pages.
Giger et al., “An Intelligent Workstation for Computer-aided Diagnosis”, in RadioGraphics, May 1993, 13:3 pp. 647-656; 10 pages.
Hologic, “Lorad StereoLoc II” Operator's Manual 9-500-0261, Rev. 005, 2004, 78 pgs.
Hologic, Inc., 510(k) Summary, prepared Nov. 28, 2010, for Affirm Breast Biopsy Guidance System Special 510(k) Premarket Notification, 5 pages.
Hologic, Inc., 510(k) Summary, prepared Aug. 14, 2012, for Affirm Breast Biopsy Guidance System Special 510(k) Premarket Notification, 5 pages.
ICRP Publication 60: 1990 Recommendations of the International Commission on Radiological Protection, 12 pages.
Jochelson, M., et al., “Bilateral Dual Energy contrast-enhanced digital mammography: Initial Experience”, RSNA 2010, 96th Scientific Assembly and Scientific Meeting, 1 page.
Jong, RA, et al., Contrast-enhanced digital mammography: initial clinical experience. Radiology 2003; 228:842-850.
Kopans, et al. Will tomosynthesis replace conventional mammography? Plenary Session SFN08: RSNA 2005.
Lehman, CD, et al. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med 2007; 356:1295-1303.
Lewin,JM, et al., Dual-energy contrast-enhanced digital subtraction mammography: feasibility. Radiology 2003; 229:261-268.
Lindfors, KK, et al., Dedicated breast CT: initial clinical experience. Radiology 2008; 246(3): 725-733.
Niklason, L., et al., Digital tomosynthesis in breast imaging. Radiology. Nov. 1997; 205(2):399-406.
Poplack, SP, et al., Digital breast tomosynthesis: initial experience in 98 women with abnormal digital screening mammography. AJR Am J Roentgenology Sep. 2007 189(3):616-23.
Prionas, ND, et al., Contrast-enhanced dedicated breast CT: initial clinical experience. Radiology. Sep. 2010 256(3):714-723.
Rafferty, E et al., “Assessing Radiologist Performance Using Combined Full-Field Digital Mammography and Breast Tomosynthesis Versus Full-Field Digital Mammography Alone: Results” . . . presented at 2007 Radiological Society of North America meeting, Chicago IL.
Shrading, Simone et al., “Digital Breast Tomosynthesis-guided Vacuum-assisted Breast Biopsy: Initial Experiences and Comparison with Prone Stereotactic Vacuum-assisted Biopsy”, the Department of Diagnostic and Interventional Radiology, Univ. of Aachen, Germany, published Nov. 12, 2014, 10 pgs.
Smith, A., “Full field breast tomosynthesis”, Radiol Manage. Sep.-Oct. 2005; 27(5):25-31.
Weidner N, et al., “Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma”, New England Journal of Medicine 1991; 324:1-8.
Weidner, N, “The importance of tumor angiogenesis: the evidence continues to grow”, AM J Clin Pathol. Nov. 2004 122(5):696-703.
“Supersonic to feature Aixplorer Ultimate at ECR”, AuntiMinnie.com, 3 pages (Feb. 2018).
Bushberg, Jerrold et al., “The Essential Physics of Medical Imaging”, 3rd ed., In: “The Essential Physics of Medical Imaging, Third Edition”, Dec. 28, 2011, Lippincott & Wilkins, Philadelphia, PA, USA, XP05579051, pp. 270-272.
Dromain, Clarisse et al., “Dual-energy contrast-enhanced digital mammography: initial clinical results”, European Radiology, Sep. 14, 2010, vol. 21, pp. 565-574.
Reynolds, April, “Stereotactic Breast Biopsy: A Review”, Radiologic Technology, vol. 80, No. 5, Jun. 1, 2009, pp. 447M-464M, XP055790574.
Fischer Imaging Corp, Mammotest Plus manual on minimally invasive breast biopsy system, 2002, 8 pages. (Reference labeled D13 in 01 Opposition).
Fischer Imaging Corporation, Installation Manual, MammoTest Family of Breast Biopsy Systems, 86683G, 86684G, P-55957-IM, Issue 1, Revision 3, Jul. 2005, 98 pages. (Reference labeled D12 in 01 Opposition).
Fischer Imaging Corporation, Operator Manual, MammoTest Family of Breast Biopsy Systems, 86683G, 86684G, P-55956-OM, Issue 1, Revision 6, Sep. 2005, 258 pages. (Reference labeled D11 in 01 Opposition).
Koechli, Ossi R., “Available Sterotactic Systems for Breast Biopsy”, Renzo Brun del Re (Ed.), Minimally Invasive Breast Biopsies, Recent Results in Cancer Research 173:105-113; Springer-Verlag, 2009. (Reference labeled D10 in 01 Opposition).
E. Shaw de Paredes et al., “Interventional Breast Procedure”, published Sep./Oct. 1998 in Curr Probl Diagn Radiol, pp. 138-184. (D15 in oppo).
Burbank, Fred, “Stereotactic Breast Biopsy: Its History, Its Present, and Its Future”, published in 1996 at the Southeastern Surgical Congress, 24 pages.
Georgian-Smith, Dianne, et al., “Stereotactic Biopsy of the Breast Using an Upright Unit, a Vacuum-Suction Needle, and a Lateral Arm-Support System”, 2001, at the American Roentgen Ray Society meeting, 8 pages. (Reference labeled D10 in 0020 Opposition).
Samani, A. et al., “Biomechanical 3-D Finite Element Modeling of the Human Breast Using MRI Data”, 2001, IEEE Transactions on Medical Imaging, vol. 20, No. 4, pp. 271-279.
Yin, H.M., et al., “Image Parser: a tool for finite element generation from three-dimensional medical images”, BioMedical Engineering Online. 3:31, pp. 1-9, Oct. 1, 2004.
Sakic et al., “Mammogram synthesis using a 3D simulation. I. breast tissue model and image acquisition simulation” Medical Physics. 29, pp. 2131-2139 (2002).
Wodajo, Felasfa, MD, “Now Playing: Radiology Images from Your Hospital PACS on your iPad,” Mar. 17, 2010; web site: http://www.imedicalapps.com/2010/03/now-playing-radiology-images-from-your-hospital-pacs-on-your-ipad/, accessed on Nov. 3, 2011 (3 pages).
Pathmanathan et al., “Predicting tumour location by simulating large deformations of the breast using a 3D finite element model and nonlinear elasticity”, Medical Image Computing and Computer-Assisted Intervention, pp. 217-224, vol. 3217 (2004).
Al Sallab et al., “Self Learning Machines Using Deep Networks”, Soft Computing and Pattern Recognition (SoCPaR), 2011 Int'l. Conference of IEEE, Oct. 14, 2011, pp. 21-26.
Ghiassi, M. et al., “A Dynamic Architecture for Artificial Networks”, Neurocomputing, vol. 63, Aug. 20, 2004, pp. 397-413.
Chan, Heang-Ping et al., “ROC Study of the effect of stereoscopic imaging on assessment of breast lesions,” Medical Physics, vol. 32, No. 4, Apr. 2005, 1001-1009.
Lilja, Mikko, “Fast and accurate voxel projection technique in free-form cone-beam geometry with application to algebraic reconstruction,” Applies Sciences on Biomedical and Communication Technologies, 2008, Isabel '08, first international symposium on, IEEE, Piscataway, NJ, Oct. 25, 2008.
Pediconi, “Color-coded automated signal intensity-curve for detection and characterization of breast lesions: Preliminary evaluation of new software for MR-based breast imaging,” International Congress Series 1281 (2005) 1081-1086.
eFilm Mobile HD by Merge Healthcare, web site: http://itunes.apple.com/bw/app/efilm-mobile-hd/id405261243?mt=8, accessed on Nov. 3, 2011 (2 pages).
eFilm Solutions, eFilm Workstation (tm) 3.4, website: http://estore.merge.com/na/estore/content.aspx?productID=405, accessed on Nov. 3, 2011 (2 pages).
Van Schie, Guido, et al., “Mass detection in reconstructed digital breast tomosynthesis volumes with a computer-aided detection system trained on 2D mammograms”, Med. Phys. 40(4), Apr. 2013, 41902-1-41902-11.
Van Schie, Guido, et al., “Generating Synthetic Mammograms from Reconstructed Tomosynthesis Volumes”, IEEE Transactions on Medical Imaging, vol. 32, No. 12, Dec. 2013, 2322-2331.
Diekmann, Felix et al., “Thick Slices from Tomosynthesis Data Sets: Phantom Study for the Evaluation of Different Algorithms”, Journal of Digital Imaging, Springer, vol. 22, No. 5, Oct. 23, 2007, pp. 519-526.
Conner, Peter, “Breast Response to Menopausal Hormone Therapy—Aspects on Proliferation, apoptosis and Mammographic Density”, 2007 Annals of Medicine, 39;1, 28-41.
Glick, Stephen J., “Breast CT”, Annual Rev. Biomed. Eng., 2007, 9;501-26.
Metheany, Kathrine G. et al., “Characterizing anatomical variability in breast CT images”, Oct. 2008, Med. Phys. 35 (10); 4685-4694.
Dromain, Clarisse, et al., “Evaluation of tumor angiogenesis of breast carcinoma using contrast-enhanced digital mammography”, AJR: 187, Nov. 2006, 16 pages.
Zhao, Bo, et al., “Imaging performance of an amorphous selenium digital mammography detector in a breast tomosynthesis system”, May 2008, Med. Phys 35(5); 1978-1987.
Mahesh, Mahadevappa, “AAPM/RSNA Physics Tutorial for Residents—Digital Mammography: An Overview”, Nov.-Dec. 2004, vol. 24, No. 6, 1747-1760.
Zhang, Yiheng et al., “A comparative study of limited-angle cone-beam reconstruction methods for breast tomosythesis”, Med Phys., Oct. 2006, 33(10): 3781-3795.
Sechopoulos, et al., “Glandular radiation dose in tomosynthesis of the breast using tungsten targets”, Journal of Applied Clinical Medical Physics, vol. 8, No. 4, Fall 2008, 161-171.
Wen, Junhai et al., “A study on truncated cone-beam sampling strategies for 3D mammography”, 2004, IEEE, 3200-3204.
Ijaz, Umer Zeeshan, et al., “Mammography phantom studies using 3D electrical impedance tomography with numerical forward solver”, Frontiers in the Convergence of Bioscience and Information Technologies 2007, 379-383.
Kao, Tzu-Jen et al., “Regional admittivity spectra with tomosynthesis images for breast cancer detection”, Proc. Of the 29th Annual Int'l. Conf. of the IEEE EMBS, Aug. 23-26, 2007, 4142-4145.
Varjonen, Mari, “Three-Dimensional Digital Breast Tomosynthesis in the Early Diagnosis and Detection of Breast Cancer”, IWDM 2006, LNCS 4046, 152-159.
Taghibakhsh, f. et al., “High dynamic range 2-TFT amplified pixel sensor architecture for digital mammography tomosynthesis”, IET Circuits Devices Syst., 2007, 1(10, pp. 87-92.
Chan, Heang-Ping et al., “Computer-aided detection system for breast masses on digital tomosynthesis mammograms: Preliminary Experience”, Radiology, Dec. 2005, 1075-1080.
Related Publications (1)
Number Date Country
20210118199 A1 Apr 2021 US
Provisional Applications (1)
Number Date Country
62479008 Mar 2017 US